4/10
10:23 am
evmn
Evommune (EVMN) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $48.00 price target on the stock.
Medium
Report
Evommune (EVMN) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $48.00 price target on the stock.
4/7
10:11 am
evmn
Evommune (EVMN) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $50.00 price target on the stock.
Neutral
Report
Evommune (EVMN) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $50.00 price target on the stock.
4/6
01:38 pm
evmn
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine [Yahoo! Finance]
Low
Report
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine [Yahoo! Finance]
4/6
09:00 am
evmn
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
Medium
Report
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
3/20
08:07 am
evmn
Evommune (EVMN) was upgraded by Clear Str Llc to "strong-buy".
Medium
Report
Evommune (EVMN) was upgraded by Clear Str Llc to "strong-buy".
3/18
08:03 am
evmn
Evommune (EVMN) had its price target lowered by HC Wainwright from $65.00 to $50.00. They now have a "buy" rating on the stock.
Medium
Report
Evommune (EVMN) had its price target lowered by HC Wainwright from $65.00 to $50.00. They now have a "buy" rating on the stock.
3/17
06:52 am
evmn
Evommune (EVMN) was upgraded by Royal Bank Of Canada to "moderate buy".
Medium
Report
Evommune (EVMN) was upgraded by Royal Bank Of Canada to "moderate buy".
3/5
06:06 pm
evmn
Evommune, Inc. GAAP EPS of -$11.22, revenue of $13M [Seeking Alpha]
Medium
Report
Evommune, Inc. GAAP EPS of -$11.22, revenue of $13M [Seeking Alpha]
3/5
04:35 pm
evmn
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]
Medium
Report
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]
3/5
04:01 pm
evmn
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
Medium
Report
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
2/18
02:14 pm
evmn
Evommune (NYSE:EVMN) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Evommune (NYSE:EVMN) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
2/12
08:30 pm
evmn
Evommune Announces $125 Million Private Placement
High
Report
Evommune Announces $125 Million Private Placement
2/10
02:13 pm
evmn
Evommune (NYSE:EVMN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Low
Report
Evommune (NYSE:EVMN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
2/10
01:32 pm
evmn
Evommune (NYSE:EVMN) had its price target raised by analysts at HC Wainwright from $35.00 to $65.00. They now have a "buy" rating on the stock.
Low
Report
Evommune (NYSE:EVMN) had its price target raised by analysts at HC Wainwright from $35.00 to $65.00. They now have a "buy" rating on the stock.
2/10
07:30 am
evmn
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
High
Report
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
2/4
06:41 pm
evmn
Evommune (NYSE:EVMN) is now covered by analysts at
Weiss Ratings. They set a "sell (e)" rating on the stock.
High
Report
Evommune (NYSE:EVMN) is now covered by analysts at
Weiss Ratings. They set a "sell (e)" rating on the stock.
1/22
09:00 am
evmn
Evommune (NYSE:EVMN) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $42.00 price target on the stock.
Medium
Report
Evommune (NYSE:EVMN) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $42.00 price target on the stock.